Merck KGaA (SWX:MER)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 59.46B +30.9% |
| Revenue (ttm) | 20.32B +0.8% |
| Net Income | 1.82B -35.1% |
| EPS | 4.09 -35.0% |
| Shares Out | n/a |
| PE Ratio | 30.64 |
| Forward PE | 16.49 |
| Dividend | 2.02 (1.62%) |
| Ex-Dividend Date | Apr 27, 2026 |
| Volume | 3 |
| Open | 125.25 |
| Previous Close | 127.50 |
| Day's Range | 125.25 - 125.25 |
| 52-Week Range | 102.61 - 127.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
About Merck KGaA
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry... [Read more]
Financial Performance
In 2025, Merck KGaA's revenue was 21.10 billion, a decrease of -0.26% compared to the previous year's 21.16 billion. Earnings were 2.61 billion, a decrease of -6.09%.
Financial numbers in EUR Financial StatementsNews
Merck KGaA Earnings Call Transcript: Q3 2026
Q3 organic sales growth accelerated to 5.1%, led by Life Science and Electronics, and FY 2026 guidance rose for the third time. Strong cash generation and portfolio moves supported the strategy, while Mavenclad erosion and soft consumer electronics demand remain headwinds.
Merck KGaA Quarterly report: Q3 2026
Merck KGaA has published its Q3 2026 quarterly earnings report on November 12, 2026.
Merck KGaA Earnings release: Q3 2026
Merck KGaA released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
Merck KGaA Slides: Q3 2026
Merck KGaA has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
Merck KGaA (MKKGY) Lags Q3 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -52.00% and +5.32%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Merck KGaA Slides: Q3 2026
Merck KGaA has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 12, 2026.
Merck KGaA Earnings release: Q3 2026
Merck KGaA released its Q3 2026 earnings on November 12, 2026, summarizing the period's financial results.
AI partnerships go beyond Nvidia: Merck KGaA CEO
Kai Beckmann, CEO of Merck KgaA, reflects on investment in the AI sector and the company's partnership with Nvidia upon the company's latest results.
Merck KGaA Q3 EBITDA Pre Edges Up On Sales Growth; Lifts FY26 Outlook
(RTTNews) - German science and technology major Merck KGaA (MKKGY, MRCG.DE, MRK.DE) reported Thursday lower net profit in its third quarter, while EBITDA pre, a key earnings metric, edged up from last...
Germany's Merck raises 2026 guidance for third time
German drugmaker Merck KGaA on Thursday raised its 2026 core profit guidance for the third time this year, helped by better underlying performance, foreign exchange effects and the acquisition of US...
Germany's Merck Raises Guidance Again on Growth Across Units
The conglomerate said it now expects full-year net sales to range between $23.84 billion and $24.29 billion, against its prior forecast of between $23.29 billion and $24.18 billion.
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically ...
Earnings Preview: Merck KGaA (MKKGY) Q3 Earnings Expected to Decline
Merck KGaA (MKKGY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MilliporeSigma: Merck KGaA, Darmstadt, Germany Hosts Change Chemistry European Forum To Advance Safety and Sustainability in Chemistry
NORTHAMPTON, MA / ACCESS Newswire / November 4, 2026 / Merck KGaA, Darmstadt, Germany, recently hosted Change Chemistry at its global headquarters for the nonprofit organization's 2026 European For...
Lonza to buy five US sites from Merck KGaA
Contract drug manufacturer Lonza said on Tuesday it would buy five US manufacturing sites from Merck KGaA, more than doubling its footprint in the country and expanding its capabilities to produce ad...
Lonza Group To Buy Merck's CDMO Business
(RTTNews) - Lonza Group (LONN.SW, LZAGF.PK) said on Tuesday that it has inked a deal to acquire five contract development and manufacturing organization, CDMO, sites in the U.S. from Merck KGaA (MRCG....
Adhoc: Lonza Group AG: Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence
Lonza Group AG / Key word(s): Acquisition Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence 03-Nov-2026 / 07:05 CET/CE...
Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence
Lonza Group AG / Key word(s): Acquisition Lonza Signs Agreement to Acquire US CDMO Network from Merck KGaA, Darmstadt, Germany, and Significantly Expands its US Presence 03-Nov-2026 / 07:05 CET/CEST R...
Merck KGaA
MilliporeSigma: 10 Years, 10 Stories: From Curiosity to Career
NORTHAMPTON, MA / ACCESS Newswire / October 30, 2026 / Over the past decade, employees at MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, have turned a ...
EMD Serono: Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two years Tumor responses remained robust1 and durable2 Not intended for UK-based media Merck KGaA, Darmstad...
Silence Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Silence Therapeutics plc - SLN
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Silence Therapeutics plc (NasdaqGM: SLN) to Me...
Why Merck KGaA Is Paying a 130% Premium for This Gene-Silencing Tech
Silence Therapeutics stock surges as Merck KGaA agrees to acquire the RNA drugmaker for over $1 billion.
Germany's Merck to Buy U.K. Biotech Silence Therapeutics for $1.3 Billion
Merck said it is offering $20 in cash for each American depositary share for Nasdaq-listed Silence Therapeutics, more than double the target's closing price as of Friday.
Germany's Merck buys Silence Therapeutics for $1.3 billion
German drugmaker Merck KGaA said on Monday it will acquire Silence Therapeutics in an all-cash deal for about $1.3 billion, adding precision engineered medicines and gene silencing to its portfolio.